Physician profile
Robert H Ritter
NPI 1467596734
$4,478.22
in general payments reported to CMS, 2019-2025
28 companies · $909 in 2025
The $909 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $1,552 · 2021: $386 · 2022: $665 · 2023: $326 · 2024: $278 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917 · Travel and Lodging: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.84 |
| Travel and Lodging | $596.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $1,302.00 | 2020 | |
| Procept Biorobotics Corporation | $756.65 | 2025 | |
| Astellas Pharma US INC | $706.19 | 2019-2024 | Myrbetriq, Xtandi |
| Abbvie INC. | $533.87 | 2021-2025 | Botox |
| Urogen Pharma, INC. | $122.94 | 2022-2025 | |
| Biotronik INC. | $116.25 | 2024 | Orsiro Mission |
| Urovant Sciences INC | $88.40 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $82.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $82.57 | 2022-2023 | Lynparza, Welireg, Keytruda |
| Endo Pharmaceuticals INC. | $76.09 | 2024 | Xiaflex |
| Allergan, INC. | $66.32 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $66.15 | 2020-2025 | Prolaris |
| Boston Scientific Corporation | $61.09 | 2019-2023 | Spaceoar Vue System - 10ml |
| Coloplast Corp | $50.35 | 2020-2023 | Speedicath |
| Amgen INC. | $48.17 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $46.62 | 2022-2023 | Urolift |
| Sumitomo Pharma America, INC. | $38.60 | 2023-2025 | Gemtesa |
| Genzyme Corporation | $32.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.47 | 2024 | |
| Laborie Medical Technologies Corp. | $29.29 | 2022-2025 | |
| Cook Medical LLC | $26.73 | 2023 | Fiber Dust |
| Medtronic, INC. | $24.33 | 2023 | Interstim |
| Olympus America INC. | $18.62 | 2025 | Itind System |
| Janssen Biotech, INC. | $16.80 | 2025 | Erleada |
| Axonics, INC. | $15.00 | 2023 | Axonics |
| 180 Medical, INC. | $14.34 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $14.07 | 2022 | |
| Pfizer INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ritter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.